Wall Street Zen upgraded shares of Quantum Biopharma (NASDAQ:QNTM – Free Report) from a sell rating to a hold rating in a research note issued to investors on Saturday morning.
Quantum Biopharma Price Performance
NASDAQ QNTM opened at $15.45 on Friday. The company has a market cap of $41.81 million, a PE ratio of -1.00 and a beta of 0.55. The stock’s 50 day simple moving average is $9.08 and its 200-day simple moving average is $6.57. Quantum Biopharma has a 1-year low of $2.70 and a 1-year high of $18.00.
Quantum Biopharma (NASDAQ:QNTM – Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($1.04). The firm had revenue of $2.09 million during the quarter, compared to analyst estimates of $2.09 million. On average, equities research analysts anticipate that Quantum Biopharma will post -3.27 EPS for the current fiscal year.
Hedge Funds Weigh In On Quantum Biopharma
Quantum Biopharma Company Profile
Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS.
See Also
- Five stocks we like better than Quantum Biopharma
- Why Invest in High-Yield Dividend Stocks?
- X: 1 Reason to Bet on U.S. Steel, and 1 Reason to Hold Back
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- 3 Oversold Stocks Flashing Bullish Reversal Signals
- The 3 Best Fintech Stocks to Buy Now
- With Novo Nordisk’s CEO Out, Wall Street Wants an American Leader
Receive News & Ratings for Quantum Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quantum Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.